Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1703-1709

  Fischel, Jean Louis ^a   Formento, Patricia ^a   Etienne, Marie Christine ^a   Spector, Tom ^b   Renée, Nicole ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b GLAXOSMITHKLINE   (United States)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Drug interactions; Folinic acid; Modulation; Tumor cell lines

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID;

ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MODULATION; PRIORITY JOURNAL;

EID: 0030740991     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)82455-0     Document Type: Article

References (29)

1. Peters GJ and Jansen G, Resistance to antimetabolites. In: Principles of Antineoplastic Drug Development and Pharmacology. (Eds. Schilsky RL, Milano GA, Ratain MJ), pp. 543-586. Marcel Dekker, New York, 1996.
2. Houghton JA, Maroda SJ, Philips JO and Houghton PJ, Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res 41: 144-149, 1981.
3. Mulkins MA and Heidelberger C, Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 42: 965-972, 1982.
4. Naguib FNM, El Kouni AM and Cha S, Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985.
5. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N and Milano G, A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30: 1517-1522, 1994.
6. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F and Milano G, Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
7. Porter DJ, Chestnut WG, Merrill BM and Spector T, Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236-5242, 1992.
8. Spector T, Harrington JA and Porter DJ, 5-ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243-2248, 1993.
9. Fischel JL, Etienne MC, Spector T, Formento P, Renée N, Milano G, Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991-996, 1995.
10. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Guillot T and Milano G, Wide range for optimal concentration of folinic acid in fluorouracil modulation. Experimental data on human tumour cell lines. Eur J Cancer 30A: 1522-1526, 1994.
11. Harris BE, Song R, Soong S and Diasio RB, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
12. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP and Goldman ID, Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid chromatography. J Biol Chem 257: 8171-8176, 1982.
13. Pizao PE, Peters JG, Van Ark-Otte J, Smets LA, Smitskamp-Wilms E, Winograd B, Pinedo HM and Giaccone G, Cytotoxic effects of conventional and investigational anticancer agents on subconfluent and multilayered postconfluent cultures growing in "V"-bottomed microtiter plates. In: Multilayered Postconfluent Tumor Cell Cultures as a Model for in vitro Chemosensitivity Tests, (Ed. Pizao PE), pp. 69-90. F.E.B.O druk B.V., Amsterdam, 1992.
14. Carmichael J, De Graff WG, Gazdar AF, Minna JD, Mitchell JB, Evaluation of a tetrazolium-based semi-automated colorimetric assay in assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
15. 19F nuclear magnetic resonance spectroscopy. Cancer Res 54: 4321-4326, 1994.
16. Baccanari DP, Davis ST, Knick VC and Spector T, 5-ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of fluorouracil. Proc Natl Acad Sci USA 90: 11064-11068, 1993.
17. Cao S, Rustum YM, Spector T, 5-ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54: 1507-1510, 1994.
18. Spector T, Porter DJ, Nelson DJ, Baccanari DP, Davis ST, Almond MR, Khor SP, Amyx H, Cao S and Rustum YM, 5-ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 19: 565-571, 1994.
19. Spector T, Cao S, Rustum YM, Harrington JA and Porter DT, Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55: 1239-1241, 1995.
20. Advanced Colorectal Cancer Meta-Analysis Project, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 10: 816-903, 1992.
21. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A and Macdonald JS, Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 13: 1303-1311, 1995.
22. Poon MA, O'Connell MJ, Moertel CG, Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1417, 1989.
23. Wolmark N, Rockette H, Fisher B, Lawrence Wickerham D, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco P, and Joachimsen P, The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
24. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J, Dimitrov N, Prigh R, Wickerham DL, Wieland S and Fisher B, The relative efficacy of 5FU + leucovorin (FU-LV), 5FU + levamisole (FU-LEV) and 5-FU + Leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-04. Proc A.S.C.O. 15: 205, 1996.
25. Cao S, Frank C, Shirasaka T and Rustum Y, 5-fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1: 839-845, 1995.
26. Cao S, Baccanari DP, Joyner SS, Davis ST, Rustum YM and Spector T, 5-ethynyluracil (776C85): Effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res 55: 6227-6230, 1995.
27. Fleming RA, Milano G, Etienne MC, Renée N, Thyss A, Schneider M and Demard F, No effect of dose, hepatic function, or nutritional status on 5FU clearance following 5-days continuous 5FU infusion. Br J Cancer 66: 668-672, 1992.
28. Khor SP, Lucas S, Schilsky R, Burris H, Von Hoff DD, Zhang R and Spector T, A phase I pharmacokinetic study of 5-ethynyluracil plus 5-fluorouracil in cancer patients with solid tumors. Proc A.A.C.R. 36: 241, 1995.
29. Priest DG, Schmitz JC, Bunni MA, Stuart RK, Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83: 1806-1812, 1991.